Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials
Shaodong Hong,1,* Wenfeng Fang,1,* Wenhua Liang,1,* Yue Yan,1 Ting Zhou,1 Tao Qin,1 Xuan Wu,1 Yuxiang Ma,1 Yuanyuan Zhao,1 Yunpeng Yang,1 Zhihuang Hu,1 Cong Xue,1 Xue Hou,1 Yue Chen,2 Yan Huang,1 Hongyun Zhao,1 Li Zhang1 1State Key Laboratory of Oncology in South China, Collaborative Innovation Cen...
Main Authors: | Hong SD, Fang WF, Liang WH, Yan Y, Zhou T, Qin T, Wu X, Ma YX, Zhao YY, Yang YP, Hu ZH, Xue C, Hou X, Chen Y, Huang Y, Zhao HY, Zhang L |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-10-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/risk-of-treatment-related-deaths-with-vascular-endothelial-growth-fact-peer-reviewed-article-OTT |
Similar Items
-
Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis
by: Ma Q, et al.
Published: (2015-08-01) -
Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
by: Sarah Waliany, MD, MS, et al.
Published: (2019-09-01) -
Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
by: Zhang XK, et al.
Published: (2015-05-01) -
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
by: John J. Ryan, MD
Published: (2016-12-01) -
Crizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death
by: Peng Liu, et al.
Published: (2019-07-01)